التفاصيل البيبلوغرافية
| العنوان: |
Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. |
| المؤلفون: |
Quah, Nicole QX, Javed, Khawaja Muhammad Ammar Ali, Arbi, Lamees, Hanumunthadu, Daren |
| المصدر: |
Clinical Ophthalmology; May2024, Vol. 18, p1479-1490, 12p |
| مصطلحات موضوعية: |
MACULAR degeneration, MACULAR edema, ENDOTHELIAL growth factors, OPTICAL coherence tomography, DIABETIC retinopathy, POLYPOIDAL choroidal vasculopathy |
| مستخلص: |
Purpose: The purpose of this study was to assess preliminary real-world outcomes in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) treated with intravitreal faricimab. Patients and Methods: This was a retrospective, observational consecutive-case real-world study of patients with nAMD or DME initiated on intravitreal faricimab between November 2022 and April 2023. Treatment-naïve patients and patients previously treated with alternate anti-vascular endothelial growth factor (anti-VEGF) agents were initiated on an intended treatment plan of four monthly faricimab injections as a loading regime. Efficacy was assessed across four treatment groups. Primary outcomes assessed for both cohorts were changes in best corrected visual acuity (BCVA) and central subfield thickness (CST) on optical coherence tomography (OCT). Secondary outcomes were alterations in OCT-defined structural features. Results: From 127 patients, 146 eyes received at least one dose of faricimab. Mean BCVA, measured in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, from baseline to fifth visit increased from: 59.0± 12.8 to 62.2± 14.3 in treatment-naïve nAMD; 61.1± 17.6 to 63.5± 14.8 in previously-treated nAMD; 61.1± 13.0 to 72.8± 11.5 in treatment-naïve DME; and 60.8± 14.6 to 63.3± 15.6 in previously-treated DME. Mean CST reduced in all four treatment groups between initiation to final loading dose, from: 442.8± 172.0μm to 305.2± 117.0μm (p< 0.0001) in treatment-naïve nAMD; 355.2± 115.1μm to 297.9± 92.54μm (p< 0.0001) in previously-treated nAMD; 465.8± 109.1μm to 343.1± 100.3μm (p< 0.0001) in treatment-naïve DME; and 492.5± 133.1μm to 388.5± 131.4μm (p< 0.0001) in previously-treated DME. Conclusion: Real-world outcomes showed some improvement in BCVA and CST for nAMD and DME following faricimab administration, including in patients previously treated with other anti-VEGF agents. Further work involving larger cohorts over longer periods is required to determine whether improvement is maintained, and if intervals can be extended to match those observed in clinical trials. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Ophthalmology is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
PDF full text from Publisher 
Full Text Finder